High-dose Intravenous N-Acetylcysteine in Mechanically Ventilated Patients with COVID-19 Pneumonia: A Propensity-Score Matched Cohort Study

Abstract

Background

Current therapies for severe COVID-19, such as steroids and immunomodulators are associated with various side effects. N-acetylcysteine (NAC) has emerged as a potential adjunctive therapy with minimal side effects for patients with cytokine storm due to COVID-19. However, evidence supporting high-dose intravenous NAC in severe COVID-19 pneumonia requiring mechanical ventilation is limited.

Methods

We conducted a retrospective analysis of consecutive patients aged ≥ 18 who were admitted for acute respiratory failure (PaO2/FiO2 ratio <300) with SARS-CoV-2 infection to the Intensive Care Unit (ICU) of Queen Elizabeth Hospital from fifth July 2020 to 31^st October 2022. Inclusion was limited to patients who required mechanical ventilation. High-dose NAC refers to a dosage of 10 g per day. The primary outcome was all-cause mortality within 28 days. Propensity-score matched analysis using logistic regression was performed.

Results

Among the 136 patients analyzed, 42 (40.3%) patients received NAC. The unmatched NAC patients displayed a higher day-28 mortality (12 (28.6%) versus 4 (6.5%), p = 0.005) and fewer ventilator-free days (18.5 (0-23.0) versus 22.0 (18.3-24.0), p = 0.015). No significant differences were observed in ICU and hospital length of stays among survivors. In patients who were not treated with tocilizumab, those receiving NAC exhibited a trend toward a quicker reduction in C-reactive protein compared to those who did not receive NAC.

After propensity score matching which included 64 patients with 33 (51.6%) receiving NAC, no significant differences were found in 28-day mortality, ventilator-free days, or ICU and hospital length of stay. After adjusting for potential confounders, logistic regression of the propensity score-matched population did not demonstrate that the use of NAC independently affected 28-day mortality.

Conclusions

In patients with COVID-19 pneumonia requiring mechanical ventilation and receiving standard COVID-19 treatment, the addition of high-dose NAC did not lead to improved clinical outcomes.

Keywords

N-acetylcysteine COVID-19 pneumonia C-reactive protein adult respiratory failure intensive care unit

Get full access to this article

View all access options for this article.

References

World Health Organization: Statement on the fifteenth meeting of the IHR. 2005. Emergency Committee on the COVID-19 pandemic. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (2023). Accessed 9 July 2023.

Montazersaheb

Hosseiniyan Khatibi

Hejazi

, et al. COVID-19 infection: An overview on cytokine storm and related interventions. Virol J. 2022;19(1):92. doi: https://doi.org/10.1186/s12985-022-01814-1

Schultz

Arnold

. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990;20(3):129–147. doi: https://doi.org/10.1016/0049-0172(90)90055-k

Pepys

Hirschfield

. C-reactive protein: A critical update. J Clin Invest. 2003;111(12):1805–1812. doi: https://doi.org/10.1172/JCI18921

Lee

Gardner

Porter

, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi: https://doi.org/10.1182/blood-2014-05-552729.

National Institutes of Health: COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults–therapeutic-management/ (2023). Accessed 11 Aug 2023.

Pawar

Desai

Solomon

, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456–464. doi: https://doi.org/10.1136/annrheumdis-2018-214367

Hasanin

Mostafa

. Tocilizumab in patients with COVID-19: Which patient, time, and dose? J Anesth. 2021;35(6):896–902. doi: https://doi.org/10.1007/s00540-021-02974-0

Jorgensen

SCJ

Tse

CLY

Burry

Dresser

. Baricitinib: A review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843–856. doi: https://doi.org/10.1002/phar.2438

10.

Bahsoun

Fakih

Zareef

Bitar

Arabi

. Corticosteroids in COVID-19: Pros and cons. Front Med (Lausanne). 2023;10:1202504. doi: https://doi.org/10.3389/fmed.2023.1202504

11.

Lai

Osburga Chan

Wong

Cheng

. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med. 2010;152(10):687–688. doi: https://doi.org/10.7326/0003-4819-152-10-201005180-00017.

12.

Ibrahim

Perl

Smith

, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020;219:108544. doi: https://doi.org/10.1016/j.clim.2020.108544

13.

Assimakopoulos

Aretha

Komninos

, et al. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: A two-center retrospective cohort study. Infect Dis (Lond). 2021;53(11):847–854. doi: https://doi.org/10.1080/23744235.2021.1945675.

14.

Izquierdo

Soriano

Gonzalez

, et al. Use of N-acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci Prog. 2022;105(1):368504221074574. doi: https://doi.org/10.1177/00368504221074574

15.

Teder

Maddison

Soeorg

Meos

Karjagin

. The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit. Medicina (Kaunas). 2021;57(11). doi: https://doi.org/10.3390/medicina57111218

16.

de Alencar

JCG

Moreira

Muller

, et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;72(11):e736–ee41. doi: https://doi.org/10.1093/cid/ciaa1443

17.

Taher

Lashgari

Sedighi

Rahimi-Bashar

Poorolajal

Mehrpooya

. A pilot study on intravenous N-acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep. 2021;73(6):1650–1659. doi: https://doi.org/10.1007/s43440-021-00296-2

18.

Faverio

Rebora

Rossi

, et al. Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. ERJ Open Res. 2022;8(1):00542-2021. doi: https://doi.org/10.1183/23120541.00542-2021

19.

Avdeev

Gaynitdinova

Merzhoeva

Berikkhanov

. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. J Infect. 2022;84(1):94–118. doi: https://doi.org/10.1016/j.jinf.2021.07.003

20.

von Elm

Altman

Egger

, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Rev Esp Salud Publica. 2008;82(3):251–259.

21.

Ungheri

Pisani

Sanson

, et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol. 2000;13(3):123–128.

22.

Borgstrom

Kagedal

Paulsen

. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31(2):217–222. doi: https://doi.org/10.1007/BF00606662

23.

Olsson

Johansson

Gabrielsson

Bolme

. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34(1):77–82. doi: https://doi.org/10.1007/BF01061422

24.

Xie

Edwards

Adam

, et al. Resurgence of Omicron BA.2 in SARS-CoV-2 infection-naive Hong Kong. Nat Commun. 2023;14(1):2422. doi: https://doi.org/10.1038/s41467-023-38201-5

25.

Stuart

King

Imai

. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28.

26.

Stuart

. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25(1):1–21.

27.

Bonanad

Garcia-Blas

Tarazona-Santabalbina

, et al. The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020;21(7):915–918. doi: https://doi.org/10.1016/j.jamda.2020.05.045.

28.

Biswas

Rahaman

Biswas

Haque

Ibrahim

. Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis. Intervirology. 2021;64(1):36–47. doi: https://doi.org/10.1159/000512592

29.

Greifer N: cobalt: Covariate Balance Tables and Plots. R package version 4.5.1. https://CRAN.R-project.org/package=cobalt Accessed 5 May 2023.

30.

Izquierdo-Alonso

Perez-Rial

Rivera

Peces-Barba

. N-acetylcysteine for prevention and treatment of COVID-19: Current state of evidence and future directions. J Infect Public Health. 2022;15(12):1477–1483. doi: https://doi.org/10.1016/j.jiph.2022.11.009.

31.

Zhang

Wang

. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Medicine (Baltimore). 2018;97(45):e13087. doi: https://doi.org/10.1097/MD.0000000000013087.

32.

Sanguinetti

. N-acetylcysteine in COPD: Why, how, and when? Multidiscip Respir Med. 2015;11(1):8. doi: https://doi.org/10.1186/s40248-016-0039-2

33.

Sharafkhah

Abdolrazaghnejad

Zarinfar

Mohammadbeigi

Massoudifar

Abaszadeh

. Safety and efficacy of N-acetyl-cysteine for prophylaxis of ventilator-associated pneumonia: A randomized, double blind, placebo-controlled clinical trial. Med Gas Res. 2018;8(1):19–23. doi: https://doi.org/10.4103/2045-9912.229599

34.

Rahimi

Samimagham

Hajiabdolrrasouli

, et al. Efficacy of N-acetyl cysteine in severe COVID-19 patients: A randomized controlled phase III clinical trial. Jundishapur J Nat Pharm Prod. 2023;18(1):e129817. doi: https://doi.org/10.5812/jjnpp-129817

35.

Gamarra-Morales

Herrera-Quintana

Molina-Lopez

, et al. Response to intravenous N-acetylcysteine supplementation in critically Ill patients with COVID-19. Nutrients. 2023;15(9):2235. doi: https://doi.org/10.3390/nu15092235

36.

Infectious Diseases Society of America. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Version 4.0.0. 22 Feb 2021. https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v4.0.0.pdf Accessed 21 Nov 2023.

37.

Yang

Xie

Zhou

. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6(1):255. doi: https://doi.org/10.1038/s41392-021-00679-0.

38.

Bang

Robins

. Doubly robust estimation in missing data and causal inference models. Biometrics. 2005;61(4):962–973. doi: https://doi.org/10.1111/j.1541-0420.2005.00377.x.

39.

Shoham

Batista

Ben Amor

, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023;59:101965. doi: https://doi.org/10.1016/j.eclinm.2023.101965

40.

Marconi

Ramanan

de Bono

, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418. doi: https://doi.org/10.1016/S2213-2600(21)00331-3

41.

Kalil

Patterson

Mehta

, et al. Baricitinib plus Remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807. doi: https://doi.org/10.1056/NEJMoa2031994

42.

Recovery Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: https://doi.org/10.1016/S0140-6736(21)00676-0

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.26 MB